The analysis uncovered established subtypes and added new classifications, while also identifying a potential new treatment target.
A study from the University of Montreal adds to findings indicating the approach can help reduce sample complexity and interferences in quantitative work.
The tool is the latest such package to be released as the field continues to move towards open searching, which could significantly expand breadth of analysis.
Under the agreement, the companies will create a workflow integrating NanoString's GeoMx Digital Spatial Profiling instrument with Leica's Bond RX autostainer.
Under the agreement, Abcam will create custom panels for NanoString's GeoMx DSP platform from its collection of 6,000-plus recombinant monoclonal antibodies.
The deal will bring together the companies' respective multiplexed immunofluorescence immunohistochemistry and digital image analysis technologies.
The work suggests DIA can be a rapid way to confirm the outcome of CRISPR experiments while looking at the downstream effects of the targeted alterations.
The company is planning a 2020 commercial launch of PNNL's SLIM IMS tech, which could significantly improve the sensitivity and throughput of mass spec assays.
The company said that it plans to use Protagen's assets to further the development and commercialization of its EarlyCDT cancer diagnostics.
Developed in collaboration with Waters and Labcyte, the platform enables applications including high-throughput drug screening and metabolomic profiling.
The company hopes to commercialize the assay, and is pursuing a larger validation study, but may face competitors who have also staked claims for this indication.
Researchers brought together blood transcriptomic, metabolomic, proteomic, and immune cell profiles for dozens of West African and Australasian infants.
Olink is perhaps best known for its proximity extension assay (PEA) technology, which allows for highly sensitive, highly multiplexed protein measurements.
The company posted Q4 revenues of $10.9 million, up from $6.6 million in Q4 2017, beating the consensus Wall Street estimate of $9.3 million.
University of Kansas researchers developed the technology, which could enable faster, more sensitive analysis of exosomes than existing microfluid platforms.
However, a shift within the field towards experiments comprising larger numbers of samples and conditions may give DIA an advantage in the future.
In a recent study, researchers combined genomic and proteomic data to identify mutations responsible for a pair of rare monogenic neutrophil diseases.
The company reported revenues of $553.6 million, up from $530.5 million in Q4 2017, and beating the average analyst estimate of $544.6 million.
Revenues from mass cytometry instruments, consumables, and service increased 48 percent to $19.1 million from $12.9 million in Q4 2017.
The firms will cooperatively promote Indica's HALO image analysis tools with Fluidigm's Hyperion imaging mass cytometry platform and related products.
Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.
Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.
Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.
In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.